ReviewNature protocols2021
Testing physiologically relevant conditions in minimal inhibitory concentration assays.
Review in Nature protocols, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Mitoxantrone synergies with tigecycline againstMicrobiology spectrum · 2026Article
- Sphingosine synergizes with polymyxin antibiotics againstMicrobiology (Reading, England) · 2026Article
- A digital droplet microarray for measuring tolerance to antibiotics.bioRxiv : the preprint server for biology · 2026Article
- Fe (III)-mediated enhancement of Bacillus sp. SSAU2 resilience against Hg (II) toxicity and restoration of its Cr (VI) removal efficiency in a mercury-contaminated environment.Biodegradation · 2026Article
- The impact of inoculation methods on bacterial aggregation and antimicrobial susceptibility testing.Microbiology (Reading, England) · 2026Article
- Biology of novel LpxC inhibitors forMicrobiology spectrum · 2026Article
- Novel antimicrobial and antiangiogenic properties from riparin-type benzamides: synthesis, biological evaluation, and docking analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- Self-assembled nanonetworks of highly stable gemini surfactant-like peptides: antibacterial mechanisms, self-assembly characteristics, and in vivo anti-infection potential.Journal of nanobiotechnology · 2026Article
- Fluconazole-Decorated Gold Nanoparticles as a Novel Therapeutic Strategy Against Carbapenem-ResistantInfection and drug resistance · 2026Article
- A conserved KL2-capsule-related phage-resistant mechanism in carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Natural phenolics as multitarget antimicrobials for food preservation: mechanisms of action.Food chemistry: X · 2025Review
- Structure-Guided Development of a Potent BioA Inhibitor Validates Biotin Synthesis Inhibition as a Therapeutic Strategy for Tuberculosis.bioRxiv : the preprint server for biology · 2025Article
- Antimicrobial Peptide-Peptoid Macrocycles from the Polymyxin B2 Chemical Space.Angewandte Chemie (International ed. in English) · 2025Article
- Extreme diversity of phage amplification rates and phage-antibiotic interactions revealed by PHORCE.PLoS biology · 2025Article
- Efficacy of Lacticaseibacillus rhamnosus probiotic strains in treating chromate induced dermatitis.Scientific reports · 2025Article
- Article
- Combating oral biofilms in Nigerian schoolchildren: a synergistic approach using Macrosphyra longistyla extracts and titanium-ferrite nanoparticles.GMS hygiene and infection control · 2025Article
- Effect of daphnetin combined with tobramycin onFrontiers in immunology · 2025Article
- Assessing Cytotoxicity, Proteolytic Stability, and Selectivity of Antimicrobial Peptides: Implications for Orthopedic Applications.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The minimal inhibitory concentration (MIC) assay uses agar or broth dilution methods to measure, under defined test conditions, the lowest effective concentration of an antimicrobial agent that inhibits visible growth of a bacterium of interest. This assay is used to test the susceptibilities of bacterial isolates and of novel antimicrobial drugs, and is typically done in nutrient-rich laboratory media that have little relevance to in vivo conditions. As an extension to our original protocol on MIC assays (also published in Nature Protocols), here we describe the application of the MIC broth microdilution assay to test antimicrobial susceptibility in conditions that are more physiologically relevant to infections observed in the clinic. Specifically, we describe a platform that can be applied to the preparation of medium that mimics lung and wound exudate or blood conditions for the growth and susceptibility testing of bacteria, including ESKAPE pathogens. This protocol can also be applied to most physiologically relevant liquid medium and aerobic pathogens, and takes 3-4 d to complete.
Indexed as
Identifiers
34215865What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.